Imagine if 50 pgy-2 rad onc residents, if on July 1 they were pulled aside and told they’d be doing IM and med onc fellowships instead. It would be good for rad onc, med onc, and those 50 residents.
The med onc job market is “great, actually, it’s incredible.” It’s actually believable when a 1st year fellow on a J-1 visa says this.
Someone should make a survey asking if rad onc residents and attendings would be willing to do a 2 year fellowship to prescribe and manage systemic therapy for solid tumors.
If acgme and the other acronym time lords were okay with it, I’d bet some med onc programs would happily take a highly motivated golden era rad onc who did an IM internship. It could even be partly enfolded into residency in lieu of 12 months (up to 18-21 months) of research.
So many academic rad onc research careers built on combined modality therapy, odd that no one gives combined modality in practice.
The med onc job market is “great, actually, it’s incredible.” It’s actually believable when a 1st year fellow on a J-1 visa says this.
Someone should make a survey asking if rad onc residents and attendings would be willing to do a 2 year fellowship to prescribe and manage systemic therapy for solid tumors.
If acgme and the other acronym time lords were okay with it, I’d bet some med onc programs would happily take a highly motivated golden era rad onc who did an IM internship. It could even be partly enfolded into residency in lieu of 12 months (up to 18-21 months) of research.
So many academic rad onc research careers built on combined modality therapy, odd that no one gives combined modality in practice.
Last edited: